The case for & against
Bull & Bear analysis
Bearish
Senseonics Holdings, Inc. (NYSE: SENS) is a leading player in the medical technology sector, specializing in advanced continuous glucose monitoring (CGM) systems. The company's flagship product, Eversense, stands out as the first and only long-term implantable CGM approved for a one-year usage period, positioning it uniquely in the diabetes management market. With its focus on enhancing patient outcomes through innovative long-term monitoring solutions, Senseonics is at the forefront of addressing the burgeoning demand for effective diabetes care.
Bull says
- ↑Q1 revenue hit $11.7M (+85% YoY), driving gross margin to 58%.
- ↑In-house commercialization lifted margin expansion and operational control.
- ↑DTC marketing spend >$10M fueled new patient shipments +100% in Q1.
- ↑Pipeline catalysts include H1 2027 Gemini launch and CE-marked Eversense 365.
- ↑Unique one-year implantable CGM differentiates versus Dexcom and Abbott.
- ↑Strong liquidity sensitivity and high quality factors may attract investors.
Bear says
- ↓Q1 net loss $32.3M ($0.71 EPS), negative earnings yield and weak profitability factors.
- ↓2026 operating expenses of $150–160M may constrain margin gains during integration.
- ↓CGM market crowded by Dexcom, Abbott and Medtronic, risking share erosion.
- ↓DTC channel risks saturation; rising spend may yield declining conversions.
- ↓Full-year revenue guidance $60–64M, with international growth tied to CE-Mark timing.
- ↓Elevated leverage risk and high short interest suggest continued downside pressure.
Investment themes with SENS
Health Care Equipment & Supplies↑ +0.40%
Clinical instruments and devices powering patient care
ABT · ISRG · SYK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-10-2026neutral
Transcript signals
Bull points
- net revenue grew 85% year-over-year to $11.7 million compared to $6.3 million in the prior year period on the continued momentum of ever since 365 new patient additions, retention rates slightly above plan, and more of our business transitioning into the more profitable bundled pay reimbursement channel.
- We're raising our full-year 2026 global net revenue guidance to $60 to $64 million compared to $58 to $62 million previously. This updated revenue range represents notable year-over-year growth of 70% to 82%.
- We expect to see approximately 40% of the sales in the first half of the calendar year and 60% in the second half.
Bear points
- Net loss was $32.3 million or a $0.71 loss per share in the first quarter of 2026 compared to a net loss of $14.3 million or a $0.40 loss per share in the first quarter of 2025. Net loss increased by $18 million primarily due to increased expenses resulting from the costs related to taking over the commercialization and distribution of Eversense.
- Due to the integration of the commercial organization and supporting transition service agreements from Essentia, we expect operating expenses to be between $150 million and $160 million, with increases primarily in SG&A and a smaller increase in R&D for the Gemini Pivotal trial.
- We recognize the value of having the full view of the product lifecycle inside Senseonics, being more equipped to drive operational strategies, and having the control and agility to rapidly respond to market needs.
Read full transcript analysis ›